AXTI

5x model: market-cap asymmetry is 95.0/100 at roughly $6.7B current market cap, which is why size matters more here than business quality alone.

The earnings/growth score is driven by reported fundamentals, not narrative. revenue growth 39.1%, gross margin 21.3%, operating margin -5.9%, profit margin -14.7%. Component support: explosive growth 45.6, survival 69.1.

Catalyst Edge is the human-researched AI-thesis score: 78/100, with AI thesis alignment 82/100. Upstream AI optical materials: InP substrates feed EMLs, silicon-photonics transceivers, photodetectors and eventually co-packaged optics. This is a real AI infrastructure bottleneck exposure, but it is several layers upstream and exposed to export-permit/geopolitical friction. The main upside evidence: Q1 2026 revenue rose 39% YoY to $26.9M, with InP revenue of $13.6M representing just over half of revenue and driven primarily by data-center applications.; Record InP backlog reportedly exceeded $100M and Q2 guidance depends on record InP revenue above $17M.; Management plans to double InP capacity in 2026 and double again in 2027, with CPO cited as a potential late-2027+ inflection..

Technical setup comes from price action, not opinion: 20-day return 7.5%, 60-day return 165.9%, 120-day return 790.8%, 60-day relative strength vs QQQ 144.5%, 1-year max drawdown -38.6%, distance from 52-week high -27.9%, 60-day annualized volatility 174.2%. Above 50dma: True; above 200dma: True.

For June this pillar is better read as options/positioning confirmation, not social-media fluff. ATM implied volatility 154.9%, call/put OI 1.5, call/put volume 1.6, OTM call OI share 46.9%, short % float 13.2%, short ratio 0.7. Component support: options/squeeze 81.3.

Goldilox is the bull-case market-cap math: $6.7B current market cap vs $12.0B qualitative bull market cap, or about 1.78x. 5x: A real 5x would imply roughly $34B of market cap from a current quant market cap of about $6.75B. That is not a conservative 12-month base case. It would require InP to become a recognized strategic shortage, AXT to be viewed as one of the only scalable suppliers for AI/CPO substrates, China export constraints to ease or become irrelevant via China demand, and revenue capacity visibility moving toward several hundred million dollars annually with strong margins. This is a survivable right-tail option, but the quant 5x rank is mostly volatility/asymmetry plus narrative scarcity. The guardrails are: China export permits are the dominant near-term gating factor for shipments outside China.; Current quant valuation is already extreme versus current revenue: EV/sales around 57.7x, so backlog must become revenue quickly.; Demote if Q2 InP revenue misses the $17M+ record-revenue framing or export permits deteriorate.; Cut from 5x consideration if backlog declines or capacity expansion slips into 2027 without customer funding/commitments..